Literature DB >> 15736219

Primary rectus abdominis myocutaneous flap for repair of perineal and vaginal defects after extended abdominoperineal resection.

S W Bell1, N Dehni, M Chaouat, J C Lifante, R Parc, E Tiret.   

Abstract

BACKGROUND: Significant morbidity can result from perineal wounds, particularly after radiotherapy and extensive resection for cancer. Myocutaneous flaps have been used to improve healing. The purpose of this study was to evaluate the morbidity and results of primary rectus abdominis myocutaneous flap reconstruction of the vagina and perineum after extended abdominoperineal resection.
METHODS: Thirty-one consecutive patients undergoing one-stage rectus abdominis myocutaneous flap reconstruction of extensive perineal wounds were studied prospectively. Twenty-six patients had surgery for recurrent or persistent epidermoid anal cancer or low rectal cancer, and 21 had high-dose preoperative radiotherapy.
RESULTS: Three weeks after the operation, complete healing of the perineal wound was seen in 27 of the 31 patients. There were nine flap-related complications including three patients with partial flap necrosis, two with vaginal stenosis, one with vaginal scarring, one with small flap disunion and two with weakness of the anterior abdominal wall. There were no unhealed wounds at the completion of follow-up (median 9 months).
CONCLUSION: The transpelvic rectus abdominis myocutaneous flap for the reconstruction of large perineal and vaginal wounds achieves wound healing with only moderate morbidity in the majority of patients after extensive abdominoperineal resection with or without radiotherapy.

Entities:  

Mesh:

Year:  2005        PMID: 15736219     DOI: 10.1002/bjs.4857

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  25 in total

Review 1.  Surgery for recurrent rectal cancer: technical notes and management of complications.

Authors:  A H Mirnezami; P M Sagar
Journal:  Tech Coloproctol       Date:  2010-05-12       Impact factor: 3.781

2.  Biological mesh reconstruction of perineal wounds following enhanced abdominoperineal excision of rectum (APER).

Authors:  Oliver Peacock; H Pandya; T Sharp; N G Hurst; W J Speake; G M Tierney; J N Lund
Journal:  Int J Colorectal Dis       Date:  2011-10-18       Impact factor: 2.571

Review 3.  Radiotherapy and wound healing.

Authors:  Haresh L Devalia; Lucy Mansfield
Journal:  Int Wound J       Date:  2007-12-12       Impact factor: 3.315

4.  Management of nonhealing perineal wounds.

Authors:  Jill C Genua; David A Vivas
Journal:  Clin Colon Rectal Surg       Date:  2007-11

5.  A hundred patients with vertical rectus abdominis myocutaneous (VRAM) flap for pelvic reconstruction after total pelvic exenteration.

Authors:  R E Horch; W Hohenberger; A Eweida; U Kneser; K Weber; A Arkudas; S Merkel; J Göhl; J P Beier
Journal:  Int J Colorectal Dis       Date:  2014-04-22       Impact factor: 2.571

Review 6.  Perianal Crohn's disease: is there something new?

Authors:  Cesare Ruffolo; Marilisa Citton; Marco Scarpa; Imerio Angriman; Marco Massani; Ezio Caratozzolo; Nicolò Bassi
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

Review 7.  Management of the Perineal Defect after Abdominoperineal Excision.

Authors:  Colin Peirce; Sean Martin
Journal:  Clin Colon Rectal Surg       Date:  2016-06

Review 8.  Persistent perineal sinus: incidence, pathogenesis, risk factors, and management.

Authors:  Varut Lohsiriwat
Journal:  Surg Today       Date:  2009-03-12       Impact factor: 2.549

9.  Colonic flap with mucosa removed: a novel technique for pelvic reconstruction after exenteration of advanced pelvic malignancy.

Authors:  C Sahakitrungruang; P Atittharnsakul
Journal:  Tech Coloproctol       Date:  2012-08-11       Impact factor: 3.781

10.  Reconstruction of the perineum following anorectal cancer excision.

Authors:  Nicola Petrie; Graham Branagan; Caroline McGuiness; Shaun McGee; Clare Fuller; Helen Chave
Journal:  Int J Colorectal Dis       Date:  2008-08-08       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.